Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 94

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 94
---
 participate in a pension plan. As such, the relevant                                          
 pension numbers included in the table above are zero.                                                                               |

| 4 | The amounts reflect the cumulative total shareholder return of our common stock (column (f)) and the Nasdaq Biotechnology Index (column (g)) at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2020, and reinvestment of dividends, if any. |
| 5 | The dollar amounts reported represent the net income reflected in the Company’s audited financial statements for the applicable year.                                                                                                                                                        |
| 6 | As required by Item 402(v) of Regulation S-K, we have determined that HEPLISAV-B product revenue is the Company-Selected Measure.                                                                                                                                                            |

| 77 |

Required Disclosure of the Relationship Between Compensation Actually Paid and Financial Performance Measures

As required by Item 402(v) of Regulation S-K,
we are providing the following graphs to illustrate the relationship between the pay and performance figures that are included
in the pay versus performance tabular disclosure above. In addition, the first graph below further illustrates the relationship
between Company total shareholder return and that of the Nasdaq Biotechnology Index. As noted above, “compensation actually
paid” for purposes of the tabular disclosure and the following graphs were calculated in accordance with SEC rules and do
not fully represent the actual final amount of compensation earned by or actually paid to our NEOs during the applicable years.

| 78 |

Required Tabular Disclosure of Most Important Measures

The most important financial performance measures used by the Company to link CAP to the Company’s NEOs for the most recently completed fiscal year to the Company’s performance are set forth below. For further information regarding these performance metrics and their function in our executive compensation program, please see “Compensation Discussion and Analysis” beginning on page 43.

| • | HEPLISAV-B Vaccine Revenue                                                         |
| • | CpG 1018 Adjuvant Revenue                                                          |
| • | Relative TSR for Dynavax Common Stock Compared To Nasdaq Biotechnology Index       |
| • | HEPLISAV-B Vaccine Market Share As Percent of U.S. Market For Hepatitis-B Vaccines |

All information provided above under the “Item 402(v) Pay Versus Performance” heading will not be deemed to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective